1887

Chapter 102 : Human Papillomaviruses

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Human Papillomaviruses, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap102-1.gif /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap102-2.gif

Abstract:

The majority of identified human papillomaviruses (HPVs) with clinical significance are found in the genus , which includes types infecting the genital and nongenital mucosal and genital cutaneous surfaces as well as the genotypes associated with human cancers. The natural history of oral HPV less is only beginning to be evaluated, though it is clear that while high-risk (HR) HPV infection is associated with a subset of head and neck squamous cell cancers, the prevalence of oral HPV infection in the general population is substantially lower than the HPV prevalence in the genital tracts of men and women. Sample collection, transport, and storage recommendations of specimens vary based on the purpose and method of HPV testing. The morphological cellular changes characteristic of HPV infection and associated neoplasia are the basis for standard cervical cytology and are classified based on the Bethesda system. HPV DNA tests are typically performed on one to three 10-µm sections of formalin-fixed paraffin-embedded (FFPE) tissue. Sections are deparaffinized with octane and digested with a buffer containing proteinase K and a nonionic detergent. The number of commercially available assays for HPV detection has increased dramatically in recent years. HPV RNA:DNA hybrids are detected using a sandwich enzyme-linked immunosorbent assay-type reaction. One of the most characteristic features of HPV infection is the multiplicity of genotypes known to infect the anogenital tract and oral cavity. Complete genotyping has been incredibly useful as a research tool to evaluate the natural history of all genotypes in epidemiological studies.

Citation: Gravitt P, Ginocchio C. 2011. Human Papillomaviruses, p 1612-1623. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch102

Key Concept Ranking

Enzyme-Linked Immunosorbent Assay
0.44924498
HPV DNA Test
0.44626525
Human Transcription Factors
0.4041764
0.44924498
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Photograph of KA. LSILs on Pap smears are characterized by high nuclear/cytoplasmic ratios and the presence of KA, which is defined as the presence of nuclear atypia as well as a clearly defined perinuclear halo in cervical epithelial cells. Photograph courtesy of Patricia Wasserman, Division of Cytopathology, Department of Pathology and Laboratory Medicine, North Shore-LIJ Health System, Lake Success, NY.

Citation: Gravitt P, Ginocchio C. 2011. Human Papillomaviruses, p 1612-1623. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch102
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Graphic representation of the Invader chemistry in the Cervista HR HPV test. Courtesy of Hologic, Inc., and affiliates.

Citation: Gravitt P, Ginocchio C. 2011. Human Papillomaviruses, p 1612-1623. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch102
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

American Society for Colposcopy and Cervical Pathology 2006 consensus conference recommendations for HPV type 16 or 18 detection (from http://www.asccp.org/pdfs/consensus/clinical_update_20090408.pdf).

Citation: Gravitt P, Ginocchio C. 2011. Human Papillomaviruses, p 1612-1623. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch102
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555816728.chap102
1. Antonsson, A.,, S. Karanfilovska,, P. G. Lindqvist,, and B. G. Hansson. 2003. General acquisition of human papillomavirus infections of skin occurs in early infancy. J. Clin. Microbiol. 41: 2509 2514.
2. Arbyn, M.,, P. Sasieni,, C. J. Meijer,, C. Clavel,, G. Koliopoulos,, and J. Dillner. 2006. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24( Suppl. 3): S78 S89.
3. Badal, S.,, V. Badal,, I. E. Calleja-Macias,, M. Kalantari,, L. S. Chuang,, B. F. Li,, and H. U. Bernard. 2004. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 324: 483 492.
4. Badal, V.,, L. S. Chuang,, E. H. Tan,, S. Badal,, L. L. Villa,, C. M. Wheeler,, B. F. Li,, and H. U. Bernard. 2003. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J. Virol. 77: 6227 6234.
5. Bernard, H. U. 2002. Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches. Antivir. Ther. 7: 219 237.
6. Bernard, H. U.,, R. D. Burk,, Z. Chen,, K. van Doorslaer,, H. Z. Hausen,, and E. M. de Villiers. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70 79.
7. Burchell, A. N.,, H. Richardson,, S. M. Mahmud,, H. Trottier,, P. P. Tellier,, J. Hanley,, F. Coutlee,, and E. L. Franco. 2006. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am. J. Epidemiol. 163: 534 543.
8. Carter, J.J.,, L. A. Koutsky,, J. P. Hughes,, S. K. Lee,, J. Kuypers,, N. Kiviat,, and D. A. Galloway. 2000. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181: 1911 1919.
9. Castle, P. E.,, C. Porras,, W. G. Quint,, A. C. Rodriguez,, M. Schiffman,, P. E. Gravitt,, P. Gonzalez,, H. A. Katki,, S. Silva,, E. Freer,, L. J. Van Doorn,, S. Jimenez,, R. Herrero,, and A. Hildesheim. 2008. Comparison of two PCR-based human papillomavirus genotyping methods. J. Clin. Microbiol. 46: 3437 3445.
10. Castle, P. E.,, M. Schiffman,, R. D. Burk,, S. Wacholder,, A. Hildesheim,, R. Herrero,, M. C. Bratti,, M. E. Sherman,, and A. Lorincz. 2002. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev. 11: 1394 1399.
11. Castle, P. E.,, D. Solomon,, C. M. Wheeler,, P. E. Gravitt,, S. Wacholder,, and M. Schiffman. 2008. Human papillomavirus genotype specificity of Hybrid Capture 2. J. Clin. Microbiol. 46: 2595 2604.
12. Chan, B.K.,, J. Melnikow,, C. A. Slee,, R. Arellanes,, and G. F. Sawaya. 2009. Posttreatment humanpapillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am. J. Obstet. Gynecol. 200: 422.e1 422.e9.
13. Cuzick, J.,, M. Arbyn,, R. Sankaranarayanan,, V. Tsu,, G. Ronco,, M.-H. Mayrand,, J. Dillner,, and C. J. L. M. Meijer. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26: K29 K41.
14. Dalstein, V.,, S. Merlin,, C. Bali,, M. Saunier,, R. Dachez,, and C. Ronsin. 2009. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J. Virol. Methods 156: 77 83.
15. Day, S. P.,, A. Hudson,, A. Mast,, T. Sander,, M. Curtis,, S. Olson,, L. Chehak,, N. Quigley,, J. Ledford,, B. Yen-Lieberman,, D. Kohn,, D. I. Quigley,, and M. Olson. 2009. Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study. J. Clin. Virol. 45( Suppl. 1): S63 S72.
16. de Koning, M. N.,, L. Struijk,, J. N. Bavinck,, B. Kleter,, J. ter Schegget,, W. G. Quint,, and M. C. Feltkamp. 2007. Betapapillomaviruses frequently persist in the skin of healthy individuals. J. Gen. Virol. 88: 1489 1495.
17. de Pokomandy, A.,, D. Rouleau,, G. Ghattas,, S. Vezina,, P. Cote,, J. Macleod,, G. Allaire,, E. L. Franco,, and F. Coutlee. 2009. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J. Infect. Dis. 199: 965 973.
18. Dockter, J.,, A. Schroder,, C. Hill,, L. Guzenski,, J. Monsonego,, and C. Giachetti. 2009. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J. Clin. Virol. 45( Suppl. 1): S55 S61.
19. Doorbar, J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (London) 110: 525 541.
20. Dyson, N.,, P. M. Howley,, K. Munger,, and E. Harlow. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934 937.
21. Eder, P. S.,, J. Lou,, J. Huff,, and J. Macioszek. 2009. The nextgeneration Hybrid Capture High-Risk HPV DNA assay on a fully automated platform. J. Clin. Virol. 45( Suppl. 1): S85 S92.
22. Fakhry, C.,, W. H. Westra,, S. Li,, A. Cmelak,, J. A. Ridge,, H. Pinto,, A. Forastiere,, and M. L. Gillison. 2008. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 100: 261 269.
23. Feltkamp, M. C.,, M. N. de Koning,, J. N. Bavinck,, and J. Ter Schegget. 2008. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J. Clin. Virol. 43: 353 360.
24. Reference deleted.
25. The Future II StudyGroup. 2007. Quadrivalent vaccine against human papillomavirusto prevent high-grade cervical lesions. N. Engl. J. Med. 356: 19151927.
26. Garland, S.M.,, M. Hernandez-Avila,, C. M. Wheeler,, G. Perez,, D. M. Harper,, S. Leodolter,, G. W. Tang,, D. G. Ferris,, M. Steben,, J. Bryan,, F. J. Taddeo,, R. Railkar,, M. T. Esser,, H. L. Sings,, M. Nelson,, J. Boslego,, C. Sattler,, E. Barr,, and L. A. Koutsky. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356: 1928 1943.
27. Geraets, D.T.,, D. A. Heideman,, M. N. de Koning,, P. J. Snijders,, D. C. van Alewijk,, C. J. Meijer,, L. J. van Doorn,, and W. G. Quint. 2009. High-throughput genotyping of high-risk HPV by the Digene HPV Genotyping LQ Test using GP51/61-PCR and xMAP technology. J. Clin. Virol. 46( Suppl. 3): S21 S26.
28. Gillison, M.L. 2008. Human papillomavirus-relateddiseases: oropharynx cancers and potential implications for adolescent HPVvaccination. J. Adolesc. Health 43: S52 S60.
29. Giuliani, L.,, A. Coletti,, K. Syrjanen,, C. Favalli,, and M. Ciotti. 2006. Comparison of DNA sequencing and Roche Linear Array in human papillomavirus (HPV) genotyping. Anticancer Res. 26: 3939 3941.
30. Giuliano, A. R.,, B. Lu,, C. M. Nielson,, R. Flores,, M. R. Papenfuss,, J. H. Lee,, M. Abrahamsen,, and R. B. Harris. 2008. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J. Infect. Dis. 198: 827 835.
30a. Giuliano, A. R.,, J. M. Palefsky,, S. Goldstone,, E. D. Moreira, 0,, M. E. Penny,, C. Aranda,, E. Vardas,, H. Moi,, H. Jessen,, R. Hillman,, Y. H. Chang,, D. Ferris,, D. Rouleau,, J. Bryan,, J. B. Marshall,, S. Vuocolo,, E. Barr,, D. Radley,, R. M. Haupt,, and D. Guris. 2011. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364: 401 411.
31. Gravitt, P. E.,, F. Coutlee,, T. Iftner,, J. W. Sellors,, W. G. Quint,, and C. M. Wheeler. 2008. New technologies in cervical cancer screening. Vaccine 26( Suppl. 10): K42 K52.
32. Gravitt, P. E.,, M. B. Kovacic,, R. Herrero,, M. Schiffman,, C. Bratti,, A. Hildesheim,, J. Morales,, M. Alfaro,, M. E. Sherman,, S. Wacholder,, A. C. Rodriguez,, and R. D. Burk. 2007. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int. J. Cancer 121: 2787 2793.
33. Gravitt, P. E.,, C. L. Peyton,, T. Q. Alessi,, C. M. Wheeler,, F. Coutlee,, A. Hildesheim,, M. H. Schiffman,, D. R. Scott,, and R. J. Apple. 2000. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38: 357 361.
34. Gravitt, P. E.,, M. Schiffman,, D. Solomon,, C. M. Wheeler,, and P. E. Castle. 2008. A comparison of Linear Array and Hybrid Capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol. Biomarkers Prev. 17: 1248 1254.
35. Harvey, M.,, S. Stout,, C. R. Starkey,, R. Hendren,, S. Holt,, and G. C. Miller. 2009. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection. J. Clin. Virol. 45( Suppl. 1): S79 S83.
36. Hernandez, B. Y.,, K. McDuffie,, X. Zhu,, L. R. Wilkens,, J. Killeen,, B. Kessel,, M. T. Wakabayashi,, C. C. Bertram,, D. Easa,, L. Ning,, J. Boyd,, C. Sunoo,, L. Kamemoto,, and M. T. Goodman. 2005. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol. Biomarkers Prev. 14: 2550 2556.
37. Huang, S.,, B. Erickson,, N. Tang,, W. B. Mak,, J. Salituro,, J. Robinson,, and K. Abravaya. 2009. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J. Clin. Virol. 45( Suppl. 1): S19 S23.
38. Huibregtse, J. M.,, M. Scheffner,, and P. M. Howley. 1993. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell. Biol. 13: 4918 4927.
39. Jeantet, D.,, F. Schwarzmann,, J. Tromp,, W. J. Melchers,, A. A. van der Wurff,, T. Oosterlaken,, M. Jacobs,, and A. Troesch. 2009. NucliSENS EasyQ HPV v1 test—testing for oncogenic activity of human papillomaviruses. J. Clin. Virol. 45 ( Suppl. 1): S29 S37.
40. Khan, M. J.,, P. E. Castle,, A. T. Lorincz,, S. Wacholder,, M. Sherman,, D. R. Scott,, B. B. Rush,, A. G. Glass,, and M. Schiffman. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97: 1072 1079.
41. Klaes, R.,, A. Benner,, T. Friedrich,, R. Ridder,, S. Herrington,, D. Jenkins,, R. J. Kurman,, D. Schmidt,, M. Stoler,, and M. von Knebel Doeberitz. 2002. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am. J. Surg. Pathol. 26: 1389 1399.
42. Klaes, R.,, T. Friedrich,, D. Spitkovsky,, R. Ridder,, W. Rudy,, U. Petry,, G. Dallenbach-Hellweg,, D. Schmidt,, and M. von Knebel Doeberitz. 2001. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 92: 276 284.
43. Kohler, A.,, T. Forschner,, T. Meyer,, C. Ulrich,, M. Gottschling,, E. Stockfleth,, and I. Nindl. 2007. Multifocal distribution of cutaneous human papillomavirus types in hairs from different skin areas. Br. J. Dermatol. 156: 1078 1080.
44. Kreimer, A. R.,, R. S. Guido,, D. Solomon,, M. Schiffman,, S. Wacholder,, J. Jeronimo,, C. M. Wheeler,, and P. E. Castle. 2006. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol. Biomarkers Prev. 15: 908 914.
45. Lu, B.,, Y. Wu,, C. M. Nielson,, R. Flores,, M. Abrahamsen,, M. Papenfuss,, R. B. Harris,, and A. R. Giuliano. 2009. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J. Infect. Dis. 199: 362 371.
46. Mao, C.,, A. Balasubramanian,, M. Yu,, N. Kiviat,, R. Ridder,, A. Reichert,, M. Herkert,, M. vonKnebelDoeberitz,, and L. A. Koutsky. 2007. Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int. J. Cancer 120: 2435 2438.
47. Marks, M.,, S. B. Gupta,, K. L. Liaw,, E. Kim,, A. Tadesse,, F. Coutlee,, S. Sriplienchan,, D. D. Celentano,, and P. E. Gravitt. 2009. Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array using HPV52-specific TaqMan E6/E7 quantitative real-time PCR. J. Virol. Methods 156: 152 156.
48. Melnikow, J.,, C. McGahan,, G. F. Sawaya,, T. Ehlen,, and A. Coldman. 2009. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J. Natl. Cancer Inst. 101: 721 728.
49. Munger, K.,, B. A. Werness,, N. Dyson,, W. C. Phelps,, E. Harlow,, and P. M. Howley. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8: 4099 4105.
50. Paavonen, J.,, P. Naud,, J. Salmeron,, C. M. Wheeler,, S. N. Chow,, D. Apter,, H. Kitchener,, X. Castellsague,, J. C. Teixeira,, S. R. Skinner,, J. Hedrick,, U. Jaisamrarn,, G. Limson,, S. Garland,, A. Szarewski,, B. Romanowski,, F. Y. Aoki,, T. F. Schwarz,, W. A. Poppe,, F. X. Bosch,, D. Jenkins,, K. Hardt,, T. Zahaf,, D. Descamps,, F. Struyf,, M. Lehtinen,, G. Dubin,, and M. Greenacre. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301 314.
51. Partridge, J. M.,, J. P. Hughes,, Q. Feng,, R. L. Winer,, B. A. Weaver,, L. F. Xi,, M. E. Stern,, S. K. Lee,, S. F. O’Reilly,, S. E. Hawes,, N. B. Kiviat,, and L. A. Koutsky. 2007. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J. Infect. Dis. 196: 1128 1136.
52. Pett, M.,, and N. Coleman. 2007. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J. Pathol. 212: 356 367.
53. Pett, M. R.,, W. O. Alazawi,, I. Roberts,, S. Dowen,, D. I. Smith,, M. A. Stanley,, and N. Coleman. 2004. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res. 64: 1359 1368.
54. Rodriguez, A. C.,, M. Schiffman,, R. Herrero,, S. Wacholder,, A. Hildesheim,, P. E. Castle,, D. Solomon,, and R. Burk. 2008. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J. Natl. Cancer Inst . 100: 513 517.
55. Scheffner, M.,, B. A. Werness,, J. M. Huibregtse,, A. J. Levine,, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129 1136.
56. Schiller, J. T.,, and D. R. Lowy. 2009. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J. Infect. Dis. 200: 166 171.
57. Siebers, A. G.,, P. J. Klinkhamer,, M. Arbyn,, A. O. Raifu,, L. F. Massuger,, and J. Bulten. 2008. Cytologic detection of cervical abnormalities using liquid-based compared with conventional cytology: a randomized controlled trial. Obstet. Gynecol. 112: 1327 1334.
58. Siebers, A. G.,, P. J. Klinkhamer,, J. M. Grefte,, L. F. Massuger,, J. E. Vedder,, A. Beijers-Broos,, J. Bulten,, and M. Arbyn. 2009. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 302: 1757 1764.
59. Solomon, D.,, D. Davey,, R. Kurman,, A. Moriarty,, D. O’Connor,, M. Prey,, S. Raab,, M. Sherman,, D. Wilbur,, T. Wright Jr.,, and N. Young. 2002. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114 2119.
60. Solomon, D.,, J. L. Papillo,, and D. D. Davey. 2009. Statement on HPV DNA testutilization. Am. J. Clin. Pathol. 131: 768 769; discussion, 770 773.
61. Stoler, M. H.,, P. E. Castle,, D. Solomon,, and M. Schiffman. 2007. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of wellvalidated assays. Am. J. Clin. Pathol. 127: 335 337.
62. Szarewski, A.,, L. Ambroisine,, L. Cadman,, J. Austin,, L. Ho,, G. Terry,, S. Liddle,, R. Dina,, J. McCarthy,, H. Buckley,, C. Bergeron,, P. Soutter,, D. Lyons,, and J. Cuzick. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17: 3033 3042.
63. Tang, N.,, S. Huang,, B. Erickson,, W. B. Mak,, J. Salituro,, J. Robinson,, and K. Abravaya. 2009. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. J. Clin. Virol. 45( Suppl. 1): S25 S28.
64. Thai, H.,, S. Rangwala,, T. Gay,, K. Keating,, S. McLeod,, I. Nazarenko,, D. O’Neil,, D. Pfister,, and D. Loeffert. 2009. A n HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology. J. Clin. Virol. 45( Suppl. 1): S93 S97.
65. Tobian, A. A.,, D. Serwadda,, T. C. Quinn,, G. Kigozi,, P. E. Gravitt,, O. Laeyendecker,, B. Charvat,, V. Ssempijja,, M. Riedesel,, A. E. Oliver,, R. G. Nowak,, L. H. Moulton,, M. Z. Chen,, S. J. Reynolds,, M. J. Wawer,, and R. H. Gray. 2009. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N. Engl. J. Med. 360: 1298 1309.
66. Tsoumpou, I.,, M. Arbyn,, M. Kyrgiou,, N. Wentzensen,, G. Koliopoulos,, P. Martin-Hirsch,, V. Malamou-Mitsi,, and E. Paraskevaidis. 2009. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat. Rev. 35: 210 220.
67. van Hamont, D.,, M. A. van Ham,, J. M. Bakkers,, L. F. Massuger,, and W. J. Melchers. 2006. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J. Clin. Microbiol. 44: 3122 3129.
68. Velicer, C.,, X. Zhu,, S. Vuocolo,, K. L. Liaw,, and A. Saah. 2009. Prevalence and incidence of HPV genital infection in women. Sex. Transm. Dis. 36: 696 703.
69. Vinokurova, S.,, N. Wentzensen,, I. Kraus,, R. Klaes,, C. Driesch,, P. Melsheimer,, F. Kisseljov,, M. Durst,, A. Schneider,, and M. von Knebel Doeberitz. 2008. Typedependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 68: 307 313.
70. Viscidi, R. P.,, M. Schiffman,, A. Hildesheim,, R. Herrero,, P. E. Castle,, M. C. Bratti,, A. C. Rodriguez,, M. E. Sherman,, S. Wang,, B. Clayman,, and R. D. Burk. 2004. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a populationbased study in Costa Rica. Cancer Epidemiol. Biomarkers Prev. 13: 324 327.
71. Wentzensen, N.,, C. Bergeron,, F. Cas,, D. Eschenbach,, S. Vinokurova,, and M. von Knebel Doeberitz. 2005. Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 105: 461 467.
72. Winer, R. L.,, Q. Feng,, J. P. Hughes,, S. O’Reilly,, N. B. Kiviat,, and L. A. Koutsky. 2008. Risk of female human papillomavirus acquisition associated with first male sex partner. J. Infect. Dis. 197: 279 282.
73. Winer, R. L.,, J. P. Hughes,, Q. Feng,, S. O’Reilly,, N. B. Kiviat,, K. K. Holmes,, and L. A. Koutsky. 2006. Condom use and the risk of genital human papillomavirus infection in young women. N. Engl. J. Med. 354: 2645 2654.
74. Winer, R. L.,, S. K. Lee,, J. P. Hughes,, D. E. Adam,, N. B. Kiviat,, and L. A. Koutsky. 2003. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 157: 218 226.
75. Zhang, P.,, M. Nouri,, J. L. Brandsma,, T. Iftner,, and B. M. Steinberg. 1999. Induction of E6/E7 expression in cottontail rabbit papillomavirus latency following UV activation. Virology 263: 388 394.

Tables

Generic image for table
TABLE 1

Human alphapapillomavirus genotype diversity and clinical manifestations

HPVs were recently reclassified by the International Committee on Taxonomy of Viruses (ICTV). The new classification (species, ICTV) and the historical classification (species, common use) are both represented. MMPV, PV. Species are listed by type; e.g., HPV32 is HPV type 32.

Citation: Gravitt P, Ginocchio C. 2011. Human Papillomaviruses, p 1612-1623. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch102
Generic image for table
TABLE 2

Clinical indications for appropriate use of HPV tests

Adapted from reference . ASC-US: atypical squamous cells of undetermined significance; AGC, atypical glandular cells; ASC-H, atypical squamous cells, cannot exclude a high-grade SIL.

Citation: Gravitt P, Ginocchio C. 2011. Human Papillomaviruses, p 1612-1623. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch102
Generic image for table
TABLE 3

Commercially available HPV assays

NASBA, nucleic acid sequence-based amplification; TMA, transcription-mediated amplification; ASC-US, atypical squamous cells of undetermined significance.

Citation: Gravitt P, Ginocchio C. 2011. Human Papillomaviruses, p 1612-1623. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch102

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error